Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability

Familial Cancer

Volumn 14, Issue 1, 2015, Pages 117-128

  Berrino, Jacopo ^a   Berrino, Franco ^a   Francisci, Silvia ^b   Peissel, Bernard ^a   Azzollini, Jacopo ^a   Pensotti, Valeria ^c,d   Radice, Paolo ^a   Pasanisi, Patrizia ^a   Manoukian, Siranoush ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d Cogentech Cancer Genetics Test Laboratory ^*  (Italy)

Author keywords

BRCA genes; Breast cancer; Mutation probability; Ovarian cancer; Penetrance; Risk estimation model

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INCIDENCE; COMPUTER PROGRAM; DELETION MUTANT; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BAYES THEOREM; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MUTATION; OVARY TUMOR; PROCEDURES; TUMOR SUPPRESSOR GENE;

AREA UNDER CURVE; BAYES THEOREM; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; OVARIAN NEOPLASMS; PENETRANCE; ROC CURVE; SOFTWARE;

EID: 84943014288     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-014-9766-8     Document Type: Article

References (54)

1. The Breast Cancer Linkage (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316
2. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372
3. Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. Am J Hum Genet 52:678–701
4. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62:676–689
5. Narod S, Ford D, Devilee P et al (1995) Genetic heterogeneity of breast-ovarian cancer revisited. Breast cancer linkage consortium. Am J Hum Genet 57:957–958
6. Bonadona V, Sinilnikova OM, Chopin S et al (2005) Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes Chromosomes Cancer 43:404–413
7. Hopper JL, Southey MC, Dite GS et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiol Biomarkers Prev 8:741–747
8. Loman N, Bladstrom A, Johannsson O, Borg A, Olsson H (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175–R186
9. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408
10. Risch HA, McLaughlin JR, Cole DE et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98:1694–1706
11. Thorlacius S, Struewing JP, Hartge P et al (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352:1337–1339
12. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83:1301–1308
13. Mavaddat N, Peock S, Frost D et al (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812–822
14. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130
15. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333
16. Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:5898–5905
17. Claus EB, Risch N, Thompson WD (1994) Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73:643–651
18. Federico M, Maiorana A, Mangone L et al (1999) Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal. Breast Cancer Res Treat 55:213–221
19. Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20:1480–1490
20. Shattuck-Eidens D, Oliphant A, McClure M et al (1997) BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 278:1242–1250
21. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227–238
22. Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145–158
23. Andersen TI (1996) Genetic heterogeneity in breast cancer susceptibility. Acta Oncol 35:407–410
24. Berrino F, Pasanisi P, Berrino J, Curtosi P, Bellati C (2002) A European case-only study on familial breast cancer. IARC Sci Publ 156:63–65
25. Pasanisi P, Berrino J, Fusconi E, Curtosi P, Berrino F (2005) A European case-only study (COS) on familial breast cancer. J Nutr 135:3040S–3041S
26. Pasanisi P, Hédelin G, Berrino J et al (2009) Oral contraceptive use and BRCA penetrance: a case-only study. Cancer Epidemiol Biomarkers Prev 18:2107–2113
27. Pasanisi P, Bruno E, Manoukian S, Berrino F (2013) A randomized controlled trial of diet and physical activity in BRCA mutation carriers. Fam Cancer. doi:10.1007/s10689-013-9691
28. Parkin D, Whelan SL, Ferlay J (2002) Cancer incidence in five continents. IARC scientific publication no. 155. IARC Press, Lyon
29. Capocaccia R, Verdecchia A, Micheli A, Sant M, Gatta G, Berrino F (1990) Breast cancer incidence and prevalence estimated from survival and mortality. Cancer Causes Control 1:23–29
30. Chang-Claude J, Becher H, Eby N, Bastert G, Wahrendorf J, Hamann U (1997) Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 123:272–279
31. Narod SA, Goldgar D, Cannon-Albright L et al (1995) Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 64:394–398
32. Tryggvadottir L, Sigvaldason H, Olafsdottir GH et al (2006) Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920–2000. J Natl Cancer Inst 98:116–122
33. Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580–1590
34. Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC (2014) BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer 110:535–545
35. Roudgari H, Miedzybrodzka ZH, Haites NE (2008) Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models. Fam Cancer 7:199–212
36. Manoukian S, Peissel B, Pensotti V et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601–606
37. Radice P (2002) Mutations of BRCA genes in hereditary breast and ovarian cancer. J Exp Clin Cancer Res 21:9–12
38. Lindor NM, Guidugli L, Wang X et al (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33:8–21
39. Verdecchia A, Capocaccia R, Egidi V, Golini A (1989) A method for the estimation of chronic disease morbidity and trends from mortality data. Stat Med 8:201–216
40. Berrino F, Capocaccia R, Esteve J et al (1999) Survival of cancer patients in Europe: the EUROCARE-2 study. IARC scientific publications no. 151, Lyon
41. Berrino F, Capocaccia R, Coleman P et al (2003) Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 14:v1–v155
42. De Angelis G, De Angelis R, Frova L, Verdecchia A (1994) MIAMOD: a computer package to estimate chronic disease morbidity using mortality and survival data. Comput Methods Programs Biomed 44:99–107
43. Micheli A, Verdecchia A, Capocaccia R et al (1992) Estimated incidence and prevalence of female breast cancer in Italian regions. Tumori 78:13–21
44. Gonzalez-Diego P, Lopez-Abente G, Pollan M, Ruiz M (2000) Time trends in ovarian cancer mortality in Europe (1955–1993): effect of age, birth cohort and period of death. Eur J Cancer 36:1816–1824
45. Press WH, Tekolski SA, Vetterling WT, Flannery BP (1992) Numerical Recipes in C: the art of scientific computing, 2edn. Cambridge University Press, Cambridge
46. Chen S, Iversen ES, Friebel T et al (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24:863–871
47. Begg CB, Haile RW, Borg A et al (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194–201
48. Eccles SA, Aboagye EO, Ali S et al (2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 15:R92
49. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462
50. National Cancer Institute. (2013) Genetics of breast and ovarian cancer (PDQ). http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page2
51. Malone KE, Daling JR, Doody DR et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35–64 years. Cancer Res 66:8297–8308
52. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48:232–242
53. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
54. Perkins NJ, Schisterman EF (2006) The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 163:670–675